Objective To screen chemotherapeutic drugs that can synergistically inhibit the proliferation of glioblastoma cells with CCND1 by constructing CCND1-silenced and overexpressed human glioblastoma cell lines SHG-44. Methods SHG-44 cells with CCND1 silenced or overexpressed were constructed, and the expression of P-glycoprotein (P-gp, expression product of multidrug resistance gene MDR1) and apoptotic factors (Bcl-2, Caspase-3) in the cells were detected by Western blotting. The SHG-44 cells with CCND1 silenced or overexpressed were cultured with carmustine (BCNU), lomustine (CCNU) and temozolomide (TMZ), respectively; and then the available chemotherapeutic drugs were screened, which could synergistically inhibit the proliferation of tumor cells with CCND1 sliencing. Human glioblastoma cell lines U251 were used to verify the findings in SHG-44 cells. Results Western blotting analysis showed that CCND1 silencing significantly down-regulated the expressions of MDR1 and Bcl-2, and up-regulated the expression of Caspase-3 (all P<0.01). There were no significant differences in cell growth curves between the CCND1-silenced cells treating with BCNU (0.05 μg/mL, 0.25 μg/mL) and CCNU (20 μg/mL, 80 μg/mL) for 2, 3, 4, and 5 days; However, the proliferation of CCND1-silenced SHG-44 cells was significantly inhibited by TMZ (9.1 μg/mL) compared with parent SHG-44 cells on the 4^th and 5^th day after treatment (P<0.05). The findings that CCND1 silencing promoted chemosensitivity of TMZ were confirmed by U251 cell experiments. Conclusion CCND1 silencing combined with TMZ is more effective in inhibiting the proliferation of human glioblastoma cell lines SHG-44 than CCND1 silencing or TMZ alone, suggesting that CCND1 may be involved in chemotherapeutic resistance of glioblastoma cells to TMZ.